[
  {
    "ts": null,
    "headline": "Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked",
    "summary": "Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=415750c32dd44eb2cc61c516819d2d70acb6dd413015dd9c8082c94602c1f015",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734906873,
      "headline": "Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked",
      "id": 132114918,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458618835/image_458618835.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=415750c32dd44eb2cc61c516819d2d70acb6dd413015dd9c8082c94602c1f015"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?",
    "summary": "We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best stocks to buy and hold for 3 years. What to Expect From the Stock Market in 2025? On […]",
    "url": "https://finnhub.io/api/news?id=14559f2bb0f541986e7060420084766d9ae1f6dfdce167948264d5006a1f10c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734883984,
      "headline": "Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?",
      "id": 132117535,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Stocks to Buy and Hold For 3 Years. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best stocks to buy and hold for 3 years. What to Expect From the Stock Market in 2025? On […]",
      "url": "https://finnhub.io/api/news?id=14559f2bb0f541986e7060420084766d9ae1f6dfdce167948264d5006a1f10c7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Just Reassured Investors, but Is the Stock a Buy?",
    "summary": "Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (NYSE: PFE) is communicating that everything is under control.  To begin, let's compare the new outlook issued by management for 2025 with its recent performance to get a sense of how significant the coming 12 months will be for shareholders.  Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55.",
    "url": "https://finnhub.io/api/news?id=8fc1cd401f2b01ea9d6b5b0b161205cc8666893d4937a8eff71f9f8322524cc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734868800,
      "headline": "Pfizer Just Reassured Investors, but Is the Stock a Buy?",
      "id": 132108768,
      "image": "https://g.foolcdn.com/editorial/images/801612/investor-presents-paper-to-another-investor.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (NYSE: PFE) is communicating that everything is under control.  To begin, let's compare the new outlook issued by management for 2025 with its recent performance to get a sense of how significant the coming 12 months will be for shareholders.  Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55.",
      "url": "https://finnhub.io/api/news?id=8fc1cd401f2b01ea9d6b5b0b161205cc8666893d4937a8eff71f9f8322524cc7"
    }
  },
  {
    "ts": null,
    "headline": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
    "summary": "Stock market investors have plenty of reasons to celebrate as 2024 comes to a close.  Questions regarding the path of inflation and uncertainty over how many more interest rate cuts the Federal Reserve will deliver in 2025 are just some of the risks investors will need to grapple with.  One strategy to navigate this market environment is to take a more defensive approach, focusing on high-quality companies well positioned to continue delivering solid dividend income for shareholders.",
    "url": "https://finnhub.io/api/news?id=3db615d53f2f42a77f28fa62f579a6573cb9fb1d552e3862acb3bef993dfe58e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734868200,
      "headline": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
      "id": 132108769,
      "image": "https://g.foolcdn.com/editorial/images/801558/dividend-healthcare-stocks-2025-bullish.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stock market investors have plenty of reasons to celebrate as 2024 comes to a close.  Questions regarding the path of inflation and uncertainty over how many more interest rate cuts the Federal Reserve will deliver in 2025 are just some of the risks investors will need to grapple with.  One strategy to navigate this market environment is to take a more defensive approach, focusing on high-quality companies well positioned to continue delivering solid dividend income for shareholders.",
      "url": "https://finnhub.io/api/news?id=3db615d53f2f42a77f28fa62f579a6573cb9fb1d552e3862acb3bef993dfe58e"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Balanced Income Fund Q3 2024 Commentary",
    "summary": "Hartford Balanced Income Fund (I-share) underperformed its benchmark. US equities rose for the fourth consecutive quarter to register a robust year-to-date gain.",
    "url": "https://finnhub.io/api/news?id=9e8cb44ef71d850f5af500cfc4404ebcd544e2ba61100dfd60bd3c361327c19c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734865140,
      "headline": "Hartford Balanced Income Fund Q3 2024 Commentary",
      "id": 132110138,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1331374129/image_1331374129.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Hartford Balanced Income Fund (I-share) underperformed its benchmark. US equities rose for the fourth consecutive quarter to register a robust year-to-date gain.",
      "url": "https://finnhub.io/api/news?id=9e8cb44ef71d850f5af500cfc4404ebcd544e2ba61100dfd60bd3c361327c19c"
    }
  },
  {
    "ts": null,
    "headline": "‘Heartless’ multinationals exploiting pensions loophole for UK workers",
    "summary": "Hewlett Packard, American Express and Pfizer among firms to have frozen increases in payouts despite inflation",
    "url": "https://finnhub.io/api/news?id=c4e052b6c9b60b4156ef6fbbc6c0f88b74248d5845ada71a55ff0fb5bb1ee013",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734854444,
      "headline": "‘Heartless’ multinationals exploiting pensions loophole for UK workers",
      "id": 132106604,
      "image": "https://media.zenfs.com/en/theguardian_763/59edbc3257ce75862e012be71b2f561d",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Hewlett Packard, American Express and Pfizer among firms to have frozen increases in payouts despite inflation",
      "url": "https://finnhub.io/api/news?id=c4e052b6c9b60b4156ef6fbbc6c0f88b74248d5845ada71a55ff0fb5bb1ee013"
    }
  }
]